Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 86, Issue 4, Pages 442-446Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2009.115
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research Clinician Scientist Award
- National Alliance for Research on Schizophrenia and Depression Young Investigator and Independent Investigator
- Ontario Mental Health Foundation
- Endowed Chair in Addiction Psychiatry at University of Toronto
- National Institute on Drug Abuse [5R01-DA-015757]
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015757] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Schizophrenia is a neuropsychiatric disorder involving disturbances of perception, cognition, and behavior. It is associated with deficits in gamma-aminobutyric acid (GABA) neurotransmission; clozapine, regarded as the most effective antipsychotic, is associated with potentiation of GABA. In this article, we describe the pharmacology of clozapine vis-a-vis schizophrenia, discuss current evidence linking clozapine to GABAergic neurotransmission, and highlight alternative treatment methods that may lead to improved outcomes through the GABAergic system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
